Can the Local Agent and Distributor Be the Same Entity?

Answer: In many jurisdictions, the local agent and the distributor can be the same legal entity, but this should not be assumed automatically. The decision depends on the target country's regulatory framework, the registration pathway, who holds or controls the registration certificate, and how regulatory responsibilities are assigned, including communication with the authority, certificate maintenance, adverse event support, and document handover. For countries with high regulatory thresholds or long approval timelines, first confirm registration feasibility, local agent arrangements, and documentation gaps, and then define the boundaries of the distribution cooperation.

Prepared by the AIMEILI Regulatory Editorial Team based on public regulatory materials, registration practice, and the medical device international registration knowledge base.

Article type: FAQ. Published: 2026-07-08 09:00. Updated: 2026-07-08 09:00.

This article outlines priority issues that medical device companies should assess in international registration, documentation preparation, compliance pathways, and post-market maintenance.

Content Structure

• Key Summary
• Assessment Logic
• Documentation Priorities
• Common Misconceptions
• AIMEILI Perspective
• Continue Reading
• Applicable Boundaries

Key Summary

National registration and local distributors should be considered together, but the registration pathway and certificate control should be designed first. Registration determines whether a product can be legally marketed; distributors determine whether the product can enter channels and reach end users. If a distributor is appointed before registration is properly addressed, risks may arise in certificate ownership, agency authority, channel replacement, and document handover. For countries with high regulatory thresholds or long timelines, it is advisable to first confirm registration feasibility, local agent arrangements, and documentation gaps before determining the boundaries of distribution cooperation.

Assessment Logic

Companies should assess the target market, registration pathway, commercial launch plan, and current documentation status in a single framework. Without an early pathway assessment, later changes to the local agent, labeling, testing, clinical evidence, or certificate maintenance can cause repeated rework.

Documentation Priorities

Cost and timeline assessments should separate official fees, third-party testing or certification fees, local agent fees, translation and notarization costs, documentation remediation costs, and ongoing maintenance costs. Looking only at application fees or official review timelines usually does not reflect the true project investment.

Common Misconceptions

A common misconception is treating the local agent as an ordinary commercial contact and overlooking its responsibilities for receiving regulatory notices, maintaining certificates, supporting adverse event handling, and handing over documentation. If agency arrangements are unclear, channel replacement and market control may be affected later.

AIMEILI Perspective

AIMEILI recommends that companies assess this question at project initiation rather than addressing it immediately before submission. A more robust approach is to complete product classification, documentation gap analysis, target country prioritization, local responsible party arrangements, and post-market maintenance planning before forming an executable registration plan.

Continue Reading

Previous: Why do foreign manufacturers often need a local agent or authorized representative?

Next: When should labels, instructions for use, and UDI usually be prepared?

Recommended Reading

• How do UDI and product classification codes affect overseas registration?
• How should medical device companies choose their first batch of target countries for overseas expansion?
• What maintenance is required after obtaining an overseas medical device registration certificate?
• How is a gap assessment of technical documentation for overseas medical device registration conducted?
• What are the technical documentation requirements for medical devices under EU MDR?
• What procedures are required for exporting Chinese medical devices to Indonesia?

Return to FAQ Center. News. Contact AIMEILI.

Content Review and Applicable Boundaries

Content author: AIMEILI Regulatory Editorial Team.

Professional review: AIMEILI Medical Device International Registration Project Team.

Source principle: Priority is given to official regulatory authorities, international organizations, standards organizations, and public regulatory materials; industry media and project experience are used only as supporting judgment.

Applicable boundaries: This article is intended for preliminary understanding, documentation preparation, and project planning. It does not replace the formal requirements of the target country regulator, testing conclusions, or legal advice.